Tempus AI
TEMAI-enabled diagnostics and clinical data company: genomic and pathology testing for oncology, cardiology and hereditary disease, plus ECG algorithms that flag signs of future atrial fibrillation and low ejection fraction, and a de-identified real-world dataset and agentic platform (Tempus Lens) for drug developers.
Regulatory filing · 7 Nov 2026Products
Selected offerings — the AI products recorded here, not the vendor's full catalogue.
-
Tempus Lens Agent platform
Agentic platform for oncology drug development that helps teams design better clinical trials, target patient subgroups faster and generate evidence from Tempus's multimodal data.
-
Tempus precision medicine platform Application
Clinical and genomic data platform that sequences patient samples and returns results to oncologists.
-
Tempus ECG-AF Application
AI algorithm that identifies ECG signs associated with future atrial fibrillation risk.
-
Tempus ECG-Low EF Application
AI algorithm that identifies ECG signs associated with low ejection fraction (heart-failure risk).
-
Generative-AI assistant for oncology providers, available in Tempus Hub and inside the EHR, that answers questions on a patient's order status, biomarker report, history and eligible clinical trials, and in the EHR transcribes visits and drafts notes and prior authorizations.
-
AI-powered platform for oncology life-sciences companies that surfaces care gaps and guideline adherence from near-real-time, de-identified multimodal patient-journey data, deployed in health systems.
Closest alternatives 2
Similar products 96
Closest alternatives are pairs a vendor page itself compares. Similar products are matched from what each product does; nothing in that group is asserted as a rivalry.
Sources
- Market cap
-
Third-party database · 27 Aug 2026 aggregator
Refreshed against the listing's own page.
- Founded
-
Wikipedia infobox "founded" field, read 2026-08-27.
- Revenue (TTM)
-
Regulatory filing · 30 Jun 2026
Trailing twelve months to 2026-06-30, added from two filings: FY2025 total net revenue $1,271,789K (10-K) - six months to 2025-06-30 $570,372K + six months to 2026-06-30 $730,602K (Q2 2026 10-Q filed 2026-07-30: "Total net revenue $ 382,486 $ 314,635 $ 730,602 $ 570,372") = $1,432,019K. Neither filing states the TTM figure itself.
- Description
-
Regulatory filing · 24 Feb 2026
FY2025 10-K, Item 1: Tempus is "one of the largest sequencers of cancer patients, and patients with other diseases, in the United States"; cardiology through Tempus Next ("Around 150 hospitals nationwide are currently powered by Tempus Next"), hereditary testing through Ambry.
Open Tempus AI in the directory
Something wrong here? Send a correction — quote this company id: tempus-ai.